Status:

SUSPENDED

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

Lead Sponsor:

Adherex Technologies, Inc.

Conditions:

Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test t...

Eligibility Criteria

Inclusion

  • Signed written informed consent
  • \> or = 18 years of age
  • Advanced or metastatic solid tumors:
  • Part 1: Histologically proven advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists
  • Part 2: Histologically proven advanced and/or metastatic solid tumor of one of the following 6 histologies, that is refractory to standard curative therapy or for which no curative therapy exists: HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and breast cancer
  • Radiologically documented measurable or evaluable (non-measurable) disease
  • Adequate performance status and organ function, as evidenced by hematologic and biochemical blood testing
  • Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the last dose of ADH300004 in this study

Exclusion

  • Cytotoxic chemotherapy, radiotherapy, or investigational drug within 28 days prior to study entry
  • Non-cytotoxic cancer therapy within 14 days prior to study entry
  • Portal hypertension with bleeding esophageal or gastric varices within the past 3 months
  • Ascites that is refractory to conservative management
  • Inability to take oral medication
  • Active peptic ulcer disease
  • Known hypersensitivity to 5-FU or ADH300004
  • Stroke, major surgery, or other major tissue injury within 30 days before study entry

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00264472

Start Date

January 1 2006

Last Update

December 15 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203